 Vyant Bio NASDAQ:VYNT Inc CEO Jay Roberts told shareholders that after its merger the company is well-positioned to pursue the discovery of novel therapeutics to treat neurological diseases such as Rett Syndrome, CDKL5 Deficiency Disorders CDD, and Parkinsons Disease, a progressive nervous system CNS disorder that affects movement. The StemoniX and Cancer Genetics merger was completed in early 2021, and Vyant Bio NASDAQ:VYNT was created to use its human cell-based microBrain and computer modeling platform, AnalytiX, to identify compounds that target neurological disorders. 